Bristol-Myers Squibb stock holds firm as ORM-6151 setback meets solid Q2 2026 margins

Bristol-Myers Squibb stock (ISIN US1078421011) closed at USD 62.84 on the New York Stock Exchange on September 17, 2026, leaving the shares about 8.4 percent below their 52-week high of USD 68.64 and roughly 47.8 percent above the 52-week low of USD 42.53 as investors weigh pipeline news against earnings strength, according to a recent market overview on a major stock portal dated September 18, 2026.

Pipeline setback with ORM-6151 shapes near-term sentiment

Sentiment around Bristol-Myers Squibb has been influenced in mid-September 2026 by the company’s decision to discontinue development of ORM-6151, a blood cancer candidate licensed from Orum Therapeutics, and to return the rights to the smaller biotech after reviewing early clinical data, as reported by edaily on September 19, 2026.

According to BowTiedBiotech on September 19, 2026, Bristol-Myers Squibb had previously committed USD 100 million to the degrader-antibody conjugate program before pulling back after seeing Phase 1 data, underscoring the high bar the company sets for its oncology pipeline.

The halt of ORM-6151 is viewed primarily as a negative for Orum Therapeutics, whose stock fell more than 33 percent in after-hours trading after the rights were returned, according to edaily, while for Bristol-Myers Squibb the impact is contained by the depth of its broader oncology and immunology portfolio.

Q2 2026 margins and growth support the valuation

At the latest closing price of USD 62.84 on September 17, 2026, Bristol-Myers Squibb stock reflects a large-cap biopharmaceutical group that has delivered Q2 2026 revenue growth of 5.7 percent alongside a profit margin of 25.57 percent, providing a quantitative counterweight to single-asset pipeline volatility, as highlighted in a recent earnings-focused analysis published on September 18, 2026 on a leading financial portal.

That Q2 2026 revenue increase of 5.7 percent suggests that the company’s top line is expanding at a mid-single-digit pace compared with the prior-year quarter, while the profit margin of 25.57 percent indicates that operational efficiency remains strong relative to many peers in the large-cap pharma sector, according to contextual sector data summarized in the same analysis.

From a valuation perspective, Bristol-Myers Squibb is trading at a discount to the broader large-cap pharma industry: the stock’s forward price/earnings ratio stands at 9.58 times 2026 earnings compared with an industry average of 18.01 times, as noted by Yahoo Finance on September 18, 2026.

The same Yahoo Finance overview reports that shares of Bristol-Myers Squibb have gained 16.5 percent year to date as of mid-September 2026, compared with 5.7 percent growth for the broader industry, illustrating that investors have already rewarded the company for its operational delivery while still pricing the stock below the sector’s average valuation multiple.

Analyst consensus and upcoming October 29 earnings date

Analyst expectations for Bristol-Myers Squibb’s earnings trajectory remain constructive: the Zacks Consensus Estimate for 2026 earnings per share has risen to USD 6.91 from USD 6.34 over the past 60 days, while the 2027 estimate has increased to USD 6.46 from USD 6.12, according to Yahoo Finance on September 18, 2026.

Based on data from the same report, Bristol-Myers Squibb currently carries a Zacks Rank 3 (Hold), reflecting a balanced analyst stance that acknowledges both the attractive valuation and the need to see how late-stage pipeline assets and products like Sotyktu contribute to medium-term growth.

An important near-term milestone for investors is the next scheduled earnings release on October 29, 2026, which is flagged as the forthcoming reporting date in recent calendar overviews of the company’s events and in a stock profile that lists Bristol-Myers Squibb’s next earnings date as October 29, 2026.

Stock level within the 52-week range

With Bristol-Myers Squibb shares at USD 62.84 on September 17, 2026, the stock trades in the upper half of its 52-week range between USD 42.53 and USD 68.64, giving investors a position that is significantly above the low yet still with room to the high if earnings, pipeline, and sector sentiment remain supportive, according to a recent range overview on a major stock portal.

Market capitalization at that level is approximately USD 129.46 billion as of September 18, 2026, placing Bristol-Myers Squibb firmly among the larger constituents of the S&P 500 Health Care sector and underlining its role as a core holding in many global pharmaceutical and healthcare equity portfolios.

More news and analyses on Bristol-Myers Squibb stock